Unlock instant, AI-driven research and patent intelligence for your innovation.

Lignan compounds combined with furanocoumarin compounds in the treatment of liver fibrosis

An anti-hepatic fibrosis and drug technology, applied in the field of biomedicine and medicine, to achieve clear mechanism and reliable curative effect

Active Publication Date: 2022-07-29
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no internationally recognized drug that is safe, effective, liver-targeted, and long-term tolerated by the FDA for the treatment of human liver fibrosis.
At the same time, the treatment of liver fibrosis still has no chemical drugs that have entered clinical application, but is limited to controlling the etiology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lignan compounds combined with furanocoumarin compounds in the treatment of liver fibrosis
  • Lignan compounds combined with furanocoumarin compounds in the treatment of liver fibrosis
  • Lignan compounds combined with furanocoumarin compounds in the treatment of liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0073] 1. Schisandrin B / werethrin in the treatment of BDL-induced liver fibrosis model mice

[0074] C57BL / 6 mice were reared adaptively for one week and fasted without food and water the day before surgery. Get surgical instruments from the disinfection supply room. The state of the mice was observed before the operation, and the mice in good condition were anesthetized with sodium barbital and depilated their abdomens. The mice were placed in a supine position, fixed on the operating table, and the surgical field of view was sterilized. Position the xiphoid process of the mouse chest with the opening, lift the skin of the midline of the abdomen slightly, open the abdomen layer by layer, fix the muscles on both sides of the abdomen and pull it slightly to the outside to expose the abdominal view, and cover the intestine with sterile wet gauze. Use a damp cotton swab to open up the lower border of the liver to locate the duodenal ligament and gently pull the ligament inward ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application discloses the use of a lignan compound in combination with a furanocoumarin compound in reducing the expression of any one or more of transforming growth factor-β1, platelet-derived growth factor, and vascular endothelial cell growth factor mRNA. Lignan compounds combined with furanocoumarin compounds significantly reduce BDL model and CCl 4 The degree of liver fibrosis in mice in the model.

Description

technical field [0001] The present application relates to the fields of biomedicine and medicine, in particular to the application of lignan compounds combined with furocoumarin compounds in the treatment of liver fibrosis. Background technique [0002] Liver disease is a major health problem worldwide. If left untreated, it may develop into liver cirrhosis, portal hypertension, hepatic encephalopathy and even lead to liver failure and death. Hepatic fibrosis (HF) is a chronic liver disease (including chronic viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, metabolic liver disease, parasitic liver disease, toxic liver disease and Drug-induced liver injury) is a common pathological basis, accounting for 50% of mortality in patients with liver cancer, liver failure and cirrhosis and other liver failure diseases, due to chemical toxicity, serum alanine transferase and aspartate aminotransferase Increased levels are accompan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/36A61K31/37A61P1/16
CPCA61K31/36A61K31/37A61P1/16A61K2300/00
Inventor 柏兆方肖小河艾永强左晓彬孙小茗
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL